Drug intelligence / Profile preview

3D124

Development stage: Unknown
Lead developer: 3D Medicines
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

3D124 is an mRNA-based cancer vaccine developed by 3D Medicines for the treatment of various solid tumors. The vaccine is designed to encode tumor-specific neoantigens, which are unique proteins resulting from somatic mutations in cancer cells. By introducing these mRNA sequences into the body, 3D124 aims to activate the patient's immune system, specifically eliciting neoantigen-specific T-cell responses to recognize and eliminate tumor cells. It is currently in Phase 1 clinical development.

Targets

Neuroblastoma RAS viral oncogene homolog (NRAS) neoantigen-derived peptide

Beyond the preview

Go deeper on 3D124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3D124.

Explore the full profile